These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8130802)

  • 1. [Research analysis of local immune response after intravesicular treatment with BCG: a review].
    Patard JJ; Abbou C; Chopin D
    Prog Urol; 1993 Oct; 3(5):745-51. PubMed ID: 8130802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
    de Boer EC; De Reijke TM; Vos PC; Kurth KH; Schamhart DH
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
    De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
    In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.
    Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K
    Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of bacillus Calmette-Guerin after intravesical instillation.
    Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
    J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].
    Rivera P; Inostroza J; Orio M
    Actas Urol Esp; 1996 Oct; 20(9):812-7. PubMed ID: 9065092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.
    Reyes E; Carballido J; Manzano L; Moltó L; Olivier C; Alvarez-Mon M
    Br J Cancer; 1999 Mar; 79(7-8):1162-7. PubMed ID: 10098752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition and management of patients with bladder cancer who fail BCG therapy.
    Martin FM; Kamat AM
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):815-20. PubMed ID: 19496718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin.
    Bilen CY; Inci K; Erkan I; Ozen H
    J Urol; 2003 May; 169(5):1702-5. PubMed ID: 12686812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
    De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.